One of the major problems in treatment of leukemias is multidrug resistance, which is already present at diagnosis or develops after chemotherapy. The gene expression levels of multidrug resistance resistance 1 (MDR1), breast cancer resistance protein (BCRP) and lung resistance-resistance protein (LRP) were evaluated in blood samples of 20 CLL and 24 CML patients using RT-PCR. MDR1, BCRP and LR...

Chronic lymphocytic leukaemia (CLL) is themost common adult leuvariability in the choice of starting material (i.e. exosomes, sera or plaskaemia in the Western world and is characterized by the accumulation of CD5+/CD19+/CD23+ mature B cells in the peripheral blood, bone marrow and lymphoid tissue of patients. Despite major improvements in therapy over the past decades, CLL remains essentially ...

Monoclonal B-cell lymphocytosis (MBL) is a precursor of chronic lymphocytic leukemia (CLL). Observations of MBL in blood donors raise concern that transmitted MBL may cause recipient CLL. Using a database with health information on 1.5 million donors and 2.1 million recipients, we compared CLL occurrence among 7413 recipients of blood from 796 donors diagnosed with CLL after donation cessation,...

B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the progressive accumulation of functionally incompetent, mature looking, monoclonal CD5+, CD23+ B lymphocytes in blood, bone marrow, lymph nodes and spleen/liver. CLL B cells express low levels of surface immunoglobulin (Ig)M, IgD (10% of those on normal B cells), CD21, CD22 and CD79b. Close to 99% of B-CLL lymphocytes in peripher...

As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown. Here, we measured ex vivo sensitivity of 246 blood cancers to 63 drugs alongside genome, transcriptome, and DNA methylome analysis to understand determinants of drug response. ...

Abstract Background The overall survival of oncohematological patients (pts) depends not only on the severity cancer, anticancer therapy used and comorbidity pts. most important role in management these pts is played by supervision a cardiologist. Purpose To assess effect active cardiac targeted with ibrutinib. Methods We examined observed dynamics for 5 years 217 chronic lymphocytic leukemia (...

Expression of protein kinase CK2 is frequently deregulated in cancer and mounting evidence implicates CK2 in tumorigenesis. Here, we show that CK2 is overexpressed and hyperactivated in chronic lymphocytic leukemia (CLL). Inhibition of CK2 induces apoptosis of CLL cells without significantly affecting normal B and T lymphocytes. Importantly, this effect is not reversed by coculture with OP9 str...

Type 4 cyclic adenosine monophosphate (cAMP) phosphodiesterase (PDE4) inhibitors and other agents that raise intracellular cAMP levels induce apoptosis in Bcell chronic lymphocytic leukemia (BCLL) but not in T-CLL or peripheral blood T cells. Two principal effector proteins for cAMP are protein kinase A (PKA) and EPAC (exchange protein directly activated by cAMP), a Rap guanosine 5 diphosphate ...

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy in need of new, effective, and safe therapies. The recently identified IgM receptor FcmR is overexpressed on malignant B cells in CLL and mediates the rapid internalization and lysosomal shuttling of IgM via its Fc fragment (Fcm). To exploit this internalization and trafficking pathway for targeted drug delivery, we engineered an IgM-der...